Sơ đồ site
Liên hệ
Tiếng Việt
Tiếng Anh
Thứ hai, 11/12/2023
Vắc xin SARS-COV-2 và những thông tin liên quan (cập nhật đến 25/3/2022)
Cập nhật vào: Thứ sáu - 25/03/2022 12:01
Cỡ chữ
Vắc xin đã cứu sống hàng triệu người mỗi năm. Việc phát triển vắc xin COVID-19 an toàn và hiệu quả là một bước tiến lớn trong nỗ lực toàn cầu nhằm chấm dứt đại dịch và để chúng ta quay trở lại cuộc sống bình thường. Để hiểu rõ về tác dụng cũng như những nghiên cứu về vắc xin COVID-19, Cục Thông tin KH&CN quốc gia xin giới thiệu một số bài nghiên cứu đã được xuất bản chính thức và các bài viết được chấp nhận đăng trên những cơ sở dữ liệu học thuật chính thống. Những nghiên cứu công bố trước đó trong năm 2022 được tổng hợp tại đường link cuối bài.
WILEY
1. Myocarditis following rAd26 and rAd5 vector-based COVID-19 vaccine: case report
Farah Naghashzadeh, Shadi Shafaghi, Atosa Dorudinia, Seyed Alireza Naji, Majid Marjani, Ahmad Amin, Arezoo Mohamadifar, Sima Noorali, Babak Sharif Kashani
First published: 01 February 2022
https://onlinelibrary.wiley.com/doi/epdf/10.1002/ehf2.13821
2. Genomic, immunological and clinical analysis of COVID-19 vaccine breakthrough infections in Beijing, China
Di Tian, Yang Song, Man Zhang, Yang Pan, Ziruo Ge, Yao Zhang, Xingxiang Ren, Jing Wen, Yanli Xu, Hong Guo, Peng Yang, Zhihai Chen, Wenbo Xu
First published: 02 February 2022
https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.27636
3. SARS-CoV-2-related and Covid-19 vaccine-induced thromboembolic events: A comparative review
Zeinab Mohseni Afshar, Mohammad Barary, Arefeh Babazadeh, Rezvan Hosseinzadeh, Amirmasoud Alijanpour, Seyed Rouhollah Miri, Terence T. Sio, Mark J. M. Sullman …
First published: 03 February 2022
https://onlinelibrary.wiley.com/doi/epdf/10.1002/rmv.2327
4. Safety and antibody response to inactivated COVID-19 vaccine in patients with chronic hepatitis B virus infection
Taiyu He, Yingzhi Zhou, Pan Xu, Ning Ling, Min Chen, Tianquan Huang, Biqiong Zhang, Ziqiao Yang, Ling Ao, Hu Li, Zhiwei Chen, Dazhi Zhang, Xiaofeng Shi, Yu Lei, Zhiyi Wang, Weiqun Zeng…
First published: 02 February 2022
https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.15173
5. Third Dose of SARS-CoV-2 Vaccine: A Systematic Review of 30 Published Studies
Fausto Petrelli, Andrea Luciani, Karen Borgonovo, Mara Ghilardi, Maria Chiara Parati, Daniela Petrò, Veronica Lonati, Angelo Pesenti, Mary Cabiddu
First published: 03 February 2022
https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.27644
6. Allergies and COVID-19 vaccines: An ENDA/EAACI Position paper
Annick Barbaud, Lene Heise Garvey, Alessandra Arcolaci, Knut Brockow, Francesca Mori, Cristobalina Mayorga, Patrizia Bonadonna, Marina Atanaskovic-Markovic, Luis Moral …
First published: 02 February 2022
https://onlinelibrary.wiley.com/doi/epdf/10.1111/all.15241
7. Efficacy of Antibody Response Following the Vaccination of SARS-CoV-2 Infected and Non-Infected Healthcare Workers by Two-Dose Inactive Vaccine against COVID-19
Bagnu Dundar, Kadriye Karahangil, Cagri Serdar Elgormus, Hatice Nur Halipci Topsakal
First published: 06 February 2022
https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.27649
8. SARS-CoV-2 Antibody Testing for Transplant Recipients: A Tool to Personalize Protection versus COVID-19
William A. Werbel, Dorry L. Segev
First published: 04 February 2022
https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajt.16993
9. Predictive factors of a viral neutralizing humoral response after a third dose of COVID-19 mRNA vaccine in kidney transplant recipients
Xavier Charmetant, Maxime Espi, Thomas Barba, Anne Ovize, Emmanuel Morelon, Cyrille Mathieu, Olivier Thaunat
First published: 03 February 2022
https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajt.16990
10. Erythroderma related with the first dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine in a patient with psoriasis
Oyku Durmusˡ, Neslihan Akdoganˡ, Omer Karadag, Ozay Gokoz
First published: 08 February 2022
https://onlinelibrary.wiley.com/doi/epdf/10.1111/dth.15363
SCIENCEDIRECT
1. Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI)
Vaccine, 10 December 2021, Volume 40, Issue 3 (Cover date: 24 January 2022), Pages 512-520
Mark A. Katz, Efrat Bron Harlev, Ran D. Balicer
https://www.sciencedirect.com/science/article/pii/S0264410X21015802/pdfft?md5=a829e40487d895374102e2175733c242&pid=1-s2.0-S0264410X21015802-main.pdf
2. COVID-19 vaccine guidelines was numerous in quantity but many lack transparent reporting of methodological practices
Journal of Clinical Epidemiology, 14 December 2021, Volume 144 (Cover date: April 2022), Pages 163-172
Zijun Wang, Hui Liu, Yaolong Chen
3. COVID-19 vaccine hesitancy: The effects of combining direct and indirect online opinion cues on psychological reactance to health campaigns
Computers in Human Behavior, 22 October 2021, Volume 127 (Cover date: February 2022), Article 107057
Fangcao Lu, Yanqing Sun
4. Integration of fuzzy-weighted zero-inconsistency and fuzzy decision by opinion score methods under a q-rung orthopair environment: A distribution case study of COVID-19 vaccine doses
Computer Standards & Interfaces, 25 August 2021, Volume 80 (Cover date: March 2022), Article 103572
A. S. Albahri, O. S. Albahri, M. A. Ahmed
5. COVID-19 vaccine uptake, effectiveness, and waning in 82,959 health care workers: A national prospective cohort study in Wales
Vaccine, 15 January 2022, Volume 40, Issue 8 (Cover date: 16 February 2022), Pages 1180-1189
Stuart Bedston, Ashley Akbari, Ronan A. Lyons
https://www.sciencedirect.com/science/article/pii/S0264410X21015358/pdfft?md5=7334a587ddba5da9ee1a84e4ec7cdff2&pid=1-s2.0-S0264410X21015358-main.pdf
6. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial
The Lancet, 20 January 2022, Volume 399, Issue 10323 (Cover date: 29 January–4 February 2022), Pages 461-472
Lulu BravoIgor Smolenov, Ralf Clemens
7. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial
The Lancet Respiratory Medicine, 17 November 2021, Volume 10, Issue 2 (Cover date: February 2022), Pages 167-179
Seth Toback, Eva Galiza, Paul T Heath
https://www.sciencedirect.com/science/article/pii/S2213260021004094/pdfft?md5=868025319e6fa6866c1af0865dbd0774&pid=1-s2.0-S2213260021004094-main.pdf
8. Effectiveness of inactivated COVID-19 vaccines against severe illness in B.1.617.2 (Delta) variant–infected patients in Jiangsu, China
International Journal of Infectious Diseases, 19 January 2022, Volume 116 (Cover date: March 2022), Pages 204-209
Zhiliang Hu, Bilin Tao, Jianming Wang
9. Characterizing initial COVID-19 vaccine attitudes among pregnancy-capable healthcare workers
American Journal of Obstetrics & Gynecology MFM, 22 December 2021, Volume 4, Issue 2 (Cover date: March 2022), Article 100557
Marta J. Perez, Rachel Paul, Megan E. Foeller
10. Individual factors influencing COVID-19 vaccine acceptance in between and during pandemic waves (July–December 2020)
Vaccine, 1 December 2021, Volume 40, Issue 1 (Cover date: 3 January 2022), Pages 151-161
Sara Valckx, Jonas Crèvecoeur, Thomas Neyens
11. Experience of the first 1127 COVID-19 Vaccine Allergy Safety patients in Hong Kong - Clinical outcomes, barriers to vaccination, and urgency for reform
World Allergy Organization Journal, 20 December 2021, Volume 15, Issue 1 (Cover date: January 2022), Article 100622
Valerie Chiang, Sabrina Wing Shan Mok, Philip Hei Li
https://www.sciencedirect.com/science/article/pii/S1939455121001162/pdfft?md5=6bb20b73ef890d72fc2ae34ee859f0ed&pid=1-s2.0-S1939455121001162-main.pdf
PUBMED
1. Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients.
Ogata AF, Cheng CA, Desjardins M, Senussi Y, Sherman AC, Powell M, Novack L, Von S, Li X, Baden LR, Walt DR.
Clin Infect Dis. 2022 Mar 1;74(4):715-718. doi: 10.1093/cid/ciab465.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241425/pdf/ciab465.pdf
2. Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines.
Fernandes Q, Inchakalody VP, Merhi M, Mestiri S, Taib N, Moustafa Abo El-Ella D, Bedhiafi T, Raza A, Al-Zaidan L, Mohsen MO, Yousuf Al-Nesf MA, Hssain AA, Yassine HM, Bachmann MF, Uddin S, Dermime S.
Ann Med. 2022 Dec;54(1):524-540. doi: 10.1080/07853890.2022.2031274.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843115/pdf/IANN_54_2031274.pdf
3. COVID-19 and vaccination against SARS-CoV-2 in patients with neuromyelitis optica spectrum disorders.
Jovicevic V, Ivanovic J, Andabaka M, Tamas O, Veselinovic N, Momcilovic N, Mesaros S, Pekmezovic T, Drulovic J.
Mult Scler Relat Disord. 2022 Jan; 57:103320. doi: 10.1016/j.msard.2021.103320. Epub 2021 Oct 20.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526109/pdf/main.pdf
4. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review.
Galmiche S, Luong Nguyen LB, Tartour E, de Lamballerie X, Wittkop L, Loubet P, Launay O.
Clin Microbiol Infect. 2022 Feb;28(2):163-177. doi: 10.1016/j.cmi.2021.09.036. Epub 2021 Nov 17.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595936/pdf/main.pdf
5. Covid-19 mRNA Vaccines - Six of One, Half a Dozen of the Other.
Rubin EJ, Longo DL.
N Engl J Med. 2022 Jan 13;386(2):183-185. doi: 10.1056/NEJMe2117446. Epub 2021 Dec 1.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693683/pdf/NEJMe2117446.pdf
6. Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines.
Pelletier AN, Sekaly RP, Tomalka JA.
Curr Opin Virol. 2022 Feb;52:89-101. doi: 10.1016/j.coviro.2021.11.012. Epub 2021 Dec 11.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664555/pdf/main.pdf
7. Examining COVID-19 vaccine uptake and attitudes among 2SLGBTQ+ youth experiencing homelessness.
Abramovich A, Pang N, Kunasekaran S, Moss A, Kiran T, Pinto AD.
BMC Public Health. 2022 Jan 18;22(1):122. doi: 10.1186/s12889-022-12537-x.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8764500/pdf/12889_2022_Article_12537.pdf
8. COVID-19 vaccine mandates: what are the current European public perspectives?
Montanari Vergallo G, Del Rio A, Negro F, Zaami S.
Eur Rev Med Pharmacol Sci. 2022 Jan;26(2):643-652. doi: 10.26355/eurrev_202201_27891.
https://www.europeanreview.org/wp/wp-content/uploads/643-652.pdf
9. Vaccine-induced immune thrombotic thrombocytopenia.
Klok FA, Pai M, Huisman MV, Makris M.
Lancet Haematol. 2022 Jan;9(1):e73-e80. doi: 10.1016/S2352-3026(21)00306-9. Epub 2021 Nov 11.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585488/pdf/main.pdf
10. Leukocytoclastic vasculitis after exposure to COVID-19 vaccine.
Fritzen M, Funchal GDG, Luiz MO, Durigon GS.
An Bras Dermatol. 2022 Jan-Feb;97(1):118-121. doi: 10.1016/j.abd.2021.09.003. Epub 2021 Nov 10.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578015/pdf/main.pdf
11. COVID-19 vaccines mix-and-match: The concept, the efficacy and the doubts.
Rashedi R, Samieefar N, Masoumi N, Mohseni S, Rezaei N.
J Med Virol. 2022 Apr;94(4):1294-1299. doi: 10.1002/jmv.27463. Epub 2021 Nov 30.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661746/pdf/JMV-9999-0.pdf
12. Metabolic disorders, COVID-19 and vaccine-breakthrough infections.
Stefan N.
Nat Rev Endocrinol. 2022 Feb;18(2):75-76. doi: 10.1038/s41574-021-00608-9.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647056/pdf/41574_2021_Article_608.pdf
SPRINGER NATURE
1. Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform
Nawamin Sa-nguanmoo, Katawut Namdee, Mattaka Khongkow, Uracha Ruktanonchai… in Nano Research (2022)
https://link.springer.com/content/pdf/10.1007%2Fs12274-021-3832-y.pdf
2. COVID-19 vaccine development based on recombinant viral and bacterial vector systems: combinatorial effect of adaptive and trained immunityNawamin Sa-nguanmoo, Mi-Hyun Lee, Bum-Joon Kim in Journal of Microbiology (2022)
https://link.springer.com/content/pdf/10.1007%2Fs12275-022-1621-2.pdf
3. Middle East Respiratory Syndrome coronavirus vaccine development: updating clinical studies using platform technologies
Jung-ah Choi, Jae-Ouk Kim in Journal of Microbiology (2022)
https://link.springer.com/content/pdf/10.1007%2Fs12275-022-1547-8.pdf
4. Is vaccine hesitancy justified? Benchmarking post-market vaccine risks with five commonly used medicinal products in Canada
Tuhin Maity, Ahmad von Schlegell, Christopher Longo in Canadian Journal of Public Health (2022)
https://link.springer.com/content/pdf/10.17269%2Fs41997-022-00609-9.pdf
5. Study of the epidemiology of COVID-19 in Ontario elementary and secondary school education workers: an interim analysis following the first school year
Brenda L. Coleman, Kailey Fischer, Robert Maunder… in Canadian Journal of Public Health (2022)
https://link.springer.com/content/pdf/10.17269%2Fs41997-022-00613-z.pdf
6. Humoral immunogenicity and tolerability of heterologous ChAd/BNT compared with homologous BNT/BNT and ChAd/ChAd SARS-CoV-2 vaccination in hemodialysis patients
Michael Haase, Paul Lesny, Mark Anderson, Gavin Cloherty… in Journal of Nephrology (2022)
https://link.springer.com/content/pdf/10.1007%2Fs40620-022-01247-7.pdf
7. Practice report: an Alberta Métis model for COVID-19 vaccine delivery
Keith D. King, Reagan Bartel, Ashton James… in Canadian Journal of Public Health (2022)
https://link.springer.com/content/pdf/10.17269%2Fs41997-021-00603-7.pdf
8. COVID-19 Vaccination for Frail Older Adults in Singapore - Rapid Evidence Summary and Delphi Consensus Statements
J. Gao, P. Lun, Y. Y. Ding, Pradeep Paul George in The Journal of Frailty & Aging (2022)
https://link.springer.com/content/pdf/10.14283%2Fjfa.2022.12.pdf
Các công bố về COVID-19 trước thời gian trên:
Cập nhật các công bố về COVID-19 từ ngày 11/3 đến ngày 18/3/2022
Cập nhật các công bố về COVID-19 từ ngày 4/3 đến ngày 11/3/2022
Cập nhật các công bố về COVID-19 từ ngày 25/3 đến ngày 04/3/2022
Cập nhật các công bố về COVID-19 từ ngày 18/2 đến ngày 25/2/2022
Cập nhật các công bố về COVID-19 từ ngày 11/2 đến ngày 18/2/2022
Cập nhật các công bố về COVID-19 từ ngày 4/2 đến ngày 11/2/2022
Cập nhật các công bố về COVID-19 từ ngày 21/1 đến ngày 28/1/2022
Cập nhật các công bố về COVID-19 từ ngày 14/1 đến ngày 21/1/2022
Cập nhật các công bố về COVID-19 từ ngày 7/1 đến ngày 14/1/2022
Cập nhật các công bố về COVID-19 từ ngày 101 đến ngày 7/1/2022
Nguồn: Cục Thông tin khoa học và công nghệ quốc gia, 25/3/2022
